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ABSTRACT
Sorafenib may reduce endothelial nitric oxide synthase (eNOS) activity by 
inhibiting vascular endothelial growth factor receptors (VEGF-R), leading to a decrease 
in nitric oxide production. In the Italian multicenter ePHAS (eNOS polymorphisms in 
HCC and sorafenib) study, we analyzed the role of eNOS polymorphisms in relation 
to clinical outcome in patients with hepatocellular carcinoma (HCC) receiving 
sorafenib. Our retrospective study included a training cohort of 41 HCC patients and 
a validation cohort of 87 HCC patients, all undergoing sorafenib treatment. Three 
eNOS polymorphisms (eNOS -786T>C, eNOS VNTR 27bp 4a/b and eNOS+894G>T) 
were analyzed by direct sequencing or Real Time PCR in relation to progression-
free survival (PFS) and overall survival (OS) (log-rank test). In univariate analysis, 
training cohort patients homozygous for eNOS haplotype (HT1:T-4b at eNOS-
786/eNOS VNTR) had a lower median PFS (2.6 vs. 5.8 months, P < 0.0001) and OS 
(3.2 vs.14.6 months, P = 0.024) than those with other haplotypes. In the validation 
set, patients homozygous for HT1 had a lower median PFS (2.0 vs. 6.7 months, P < 
0.0001) and OS (6.4 vs.18.0 months, P < 0.0001) than those with other haplotypes. 
Multivariate analysis confirmed this haplotype as the only independent prognostic 
factor. Our results suggest that haplotype HT1 in the eNOS gene may be capable of 
identifying a subset of HCC patients who are resistant to sorafenib.
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INTRODUCTION
Hepatocellular carcinoma (HCC) represents the most 
common primary liver cancer and is increasing in incidence 
[1]. The introduction of sorafenib has changed the clinical 
landscape of the disease, showing modest efficacy and 
reasonable tolerability [2–4]. Markers of sorafenib efficacy 
or resistance have yet to be identified [5–7].
The inhibition of VEGFR-2 by sorafenib is known 
to repress phosphoinositide 3-kinase (PI3K) and its 
downstream serine protein kinase (Akt), decreasing the 
activity of endothelium-derived nitric oxide synthase 
(eNOS) and reducing the production of the potent 
vasodilator nitric oxide (NO) [8–10]. NO, constitutively 
expressed by vascular endothelial cells, controls a variety 
of physiologic functions including neovascularization, 
angiogenesis [8, 9, 11] and pathological conditions 
[12, 13]. In particular, it appears to play a proangiogenic 
role in tumor angiogenesis [14].
Numerous studies have reported that specific eNOS 
single nucleotide polymorphisms (SNPs) affect gene 
transcription, resulting in a variation in eNOS protein 
levels and activity and consequently influencing NO 
[15, 16].
Among known polymorphisms, eNOS-786 T>C in 
the promoter region, a 27bp variable number of tandem 
repeats in intron 4 (eNOS VNTR 4a/b) and eNOS+894 
G>T in exon 7 have received the greatest attention [15, 
17, 18]. Numerous studies have investigated the extent 
to which eNOS polymorphisms influence the risk of 
developing cancer [19–21] and cardiovascular diseases 
[22–26], with conflicting results. However, it is still 
unclear how these polymorphisms affect gene expression 
and enzyme activity in cells and how they influence 
response to anti-angiogenic drugs [27]. The aim of 
the ePHAS study (eNOS polymorphisms in HCC and 
sorafenib) was to evaluate the prognostic value of eNOS 
polymorphisms in two independent cohorts of advanced 
HCC patients undergoing treatment with sorafenib.
RESULTS
Patient characteristics
The main clinical pathological characteristics of 
patients are shown in Table 1. In the training cohort the 
median follow-up was 50 months (range 1-82). Median 
progression-free survival (PFS) was 3.9 months (95% 
CI 2.7-5.7) and median overall survival (OS) was 11.3 
months (95% CI 6.7-14.9). The dose of sorafenib was 
reduced in 9 (21.9%) patients. The median follow-up in 
the validation cohort was 47 months (range 1-52). Median 
PFS was 4.6 (95% CI 2.6-5.7), while median OS was 12.4 
months (95% CI 8.2-17.2). Seventeen (19.5%) patients 
required a reduction in the dose of sorafenib. Clinical 
pathological characteristics were similar between the two 
cohorts, with the exception of median age and etiology.
Clinical variables
PFS and OS data in relation to baseline patient 
characteristics and toxicity in both cohorts are shown in 
Table 2. In particular, we found that validation cohort 
patients with a MELD score ≤10 showed better PFS 
(5.7 vs. 1.6 months, P < 0.0001) and OS (13.6 vs. 4.4 
months, P = 0.004) than those with a MELD score > 10. 
These data were not significant in the training cohort. 
With regard to hypertension, training cohort patients with 
increased systolic blood pressure (> 140 mmHg) and/
or increased diastolic blood pressure (> 90 mmHg) after 
15 days’ treatment with sorafenib showed better PFS 
(6.1 vs. 2.8 months, P = 0.005) and OS (14.6 vs.7.5 months, 
P = 0.027) than those with no hypertension. No data on 
hypertension were available for the validation cohort.
eNOS genotypes and haplotype analysis
eNOS-786 and eNOS+894 genotypes were 
successfully determined in all of the samples. eNOS 
VNTR genotype was not evaluable in 3 samples (2 in the 
training set and one in the validation set) because of their 
poor quality.
Genotype frequencies of eNOS-786, eNOS VNTR 
and eNOS+894 are shown in Supplementary Table 1 and 
all genotype frequencies followed the Hardy-Weinberg 
equilibrium. We observed a linkage disequilibrium 
between eNOS-786 and eNOS VNTR in both the training 
and validation cohorts (correlation coefficient, r2 = 0.227; 
D’= 0.85 and r2 =0.172; D’= 0.746, respectively) and 
identified a total of 4 haplotypes (HT). The most frequent 
haplotype in either cohort was HT1 (T-4b at eNOS-
786/eNOS VNTR) (58.1% in the training cohort and 62% 
in the validation cohort), followed by HT2 (C-4b) (24.2% 
and 23.4%, respectively), HT3 (C-4a) (16% and 12.2%, 
respectively) and HT4 (T-4a), this last occurring at a 
frequency of < 5% (1.6% and 2.4%, respectively).
eNOS genotypes and clinical outcome in the 
training cohort
In univariate analysis we found that all 3 SNPs 
were associated with PFS but not with OS (Table 3 and 
Supplementary Figure 1). eNOS-786 TT, eNOS VNTR 
4bb and eNOS+894 GG genotypes were significantly 
associated with a lower median PFS (2.6, 2.8 and 2.8 
months, respectively) than other genotypes (5.8, 8.5, 
and 5.5 months, respectively) (P = 0.0001, P = 0.046 
and P = 0.049, respectively). Interestingly, patients 
homozygous for HT1 had a lower median PFS than those 
with other haplotypes (2.6 vs. 5.8 months, P < 0.0001) 
(Table 3 and Figure 1A).
With regard to OS, only patients homozygous for 
haplotype HT1 had a lower median OS than those with 
other haplotypes (3.2 vs.14.6 months, respectively; 
P = 0.024) (Table 4 and Figure 1B).
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Table 1: Patient characteristics
Clinical and pathologic 
indexes
Training cohort (n=41) Validation cohort (n=87)
No. of Patients (%) No. of Patients (%) p
Median age, years (range) 72 (28-87) 67 (24-86) 0.016
Gender
 Male 32 (78.1) 60 (69.0)
 Female 9 (21.9) 27 (31.0) 0.392
Smoking habits
 No 18 (50.0) 12 (42.9)
 Yes 18 (50.0) 16 (57.1) 0.752
Etiology
 Metabolic syndrome 8 (19.5) 5 (5.7)
 Alcohol 6 (14.6) 6 (6.9)
 Viral 27 (65.8) 71 (81.7)
 Cryptogenic 0 5 (5.7) 0.017
BCLC stage
 B 8 (20.0) 20 (25.9)
 C 32 (80.0) 57 (74.1) 0.624
MELD score
 ≤10 30 (81.1) 37 (62.7)
 >10 7 (18.9) 22 (37.3) 0.093
Serum α-FP level
 ≤400 KUI/L 20 (52.6) 52 (69.3)
 >400 KUI/L 18 (47.4) 23 (30.7) 0.124
Diabetes
 No 24 (60.0) 68 (78.2)
 Yes 16 (40.0) 19 (21.8) 0.056
Sorafenib dose reduction
 No 32 (78.1) 70 (80.5)
 Yes 9 (21.9) 17 (19.5) 0.753
Portal vein thrombosis
 No 21 (70.0%) 39 (67.2%)
 Yes 9 (30.0%) 19 (32.8%) 0.982
Liver cirrhosis
No 1 (2.4%) 2 (2.2%)
Yes 40 (97.6%) 85 (97.8%) 0,954
Disease extension
 Liver only 23 (69.6%) 42 (72.4%)
 Metastatic disease 7 (30.4%) 16 (27.6%) 0.861
BCLC: Barcelona-Clinic Liver Cancer; MELD: Model For End-Stage Liver Disease
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Following adjustment for clinical covariates (age, 
gender, etiology, BCLC stage, serum α-FP level and 
MELD score), multivariate analysis confirmed eNOS-
786 and the specific haplotype of eNOS gene as the 
only independent prognostic factors predicting PFS (HR 
10.24, 95%CI 2.88-36.45, P = 0.0003; HR 9.76, 95%CI 
3.19-29.85, P < 0.0001, respectively) and OS (HR 4.98, 
95%CI 1.48-16.69, P = 0.009; HR 2.64, 95%CI 1.10-6.34, 
Table 2: PFS and OS in relation to clinical characteristics and toxicity in the two independent cohorts
Training set Validation set
No. of 
Patients
No. of 
Events
Median PFS 
(95% CI)
P No. of 
Events
Median OS  
(95% CI)
P No. of 
Patients
No. of 
Events
Median PFS  
(95% CI)
P No. of 
Events
Median OS  
(95% CI)
P
Gender
 Male 32 31 3.7 (2.6-4.7) 28 8.7 (3.9-14.9) 60 50 3.9 (2.4-6.2) 43 11.3 (8.2-17.2)
 Female 9 7 8.2 (2.2-11.2) 0.166 7 14.6 (6.6-23.0) 0.266 27 23 5.0 (2.1-6.3) 0.516 19 14.1 (5.6-27.0) 0.842
Smoking 
habits
 No 18 17 4.3 (2.6-8.5) 16 10.8 (6.8-14.6) 12 9 13.8 (2.1-27.1) 6 27.8 (14.1-35.0)
 Yes 18 17 4.2 (2.6-6.2) 0.997 17 9.8 (2.9-15.8) 0.578 16 11 2.4 (1.1-15.2) 0.112 9 5.2 (2.5-39.0) 0.125
Etiology
 Metabolic 
syndrome 8 8 3.0 (0.9-6.0) 6 6.8 (1.0-nr) 5 4 2.4 (2.1-8.7) 3 7.5 (3.7-9.9)
 Alcohol 6 6 6.7 (2.6-34.2) 6 15.3 (2.7-34.2) 6 5 13.5 (2.0-31.4) 5 14.4 (3.0-50.8)
 Viral 27 24 4.7 (2.6-5.8) 23 11.2 (6.9-15.1) 71 59 3.9 (2.5-5.7) 50 12.4 (8.2-18.0)
 Cryptogenic 0 0 - 0.195 0 - 0.458 5 5 3.4 (1.7-27.0) 0.599 4 10.5 (2.5-nr) 0.729
BCLC stage
 B 8 7 4.3 (0.5-21.6) 6 10.0 (0.5-23.0) 11 6 9.0 (4.8-27.1) 2 18.0 (14.4-nr)
 C 32 30 3.8 (2.7-5.7) 0.780 28 12.0 (6.7-14.9) 0.747 38 30 2.5 (2.0-8.7) 0.084 24 19.5 (3.7-28.8) 0.100
MELD score
 ≤10 30 29 3.9 (2.6-6.0) 26 12.0 (3.9-14.9) 37 32 5.7 (3.9-12.8) 29 13.6 (9.7-27.8)
 >10 7 6 3.8 (1.2-34.2) 0.706 6 8.5 (2.9-34.2) 0.863 22 22 1.6 (1.1-2.4) <0.0001 20 4.4 (2.5-10.9) 0.004
Serum α-FP 
level
 ≤400 KUI/L 20 18 3.8 (2.6-6.0) 16 10.1 (3.9-23.6) 52 44 5.0 (3.4-6.3) 38 12.4 (7.2-19.5)
 >400 KUI/L 18 17 4.6 (2.6-10.8) 0.327 16 12.0 (3.9-14.9) 0.809 23 20 2.4 (1.3-4.8) 0.044 18 7.5 (2.5-13.9) 0.043
Hypertension*
 No 21 20 2.8 (2.2-3.9) 19 7.5 (3.2-14.9) - 0 - 0 -
 Yes 18 17 6.1 (3.7-10.8) 0.005 15 14.6 (11.2-23.0) 0.027 - 0 - - 0 -
Skin toxicity
 No 23 21 3.8 (2.3-5.2) 19 6.9 (3.2-14.9) 53 43 2.8 (2.4-5.6) 34 13.6 (6.1-17.2)
 Yes 18 17 6.2 (2.6-10.8) 0.065 16 13.9 (7.5-16.7) 0.124 34 30 5.3 (3.7-12.8) 0.035 28 11.3 (7.2-28.6) 0.349
Diarrhea
 No 35 32 3.8 (2.6-5.8) 29 10.4 (6.7-14.9) 65 52 3.7 (2.5-6.2) 45 10.9 (6.4-18.0)
 Yes 6 6 5.0 (2.7-21.6) 0.447 6 13.9 (2.7-23.6) 0.876 22 21 5.0 (2.1-9.9) 0.365 17 13.9 (10.5-28.8) 0.301
Asthenia
 No 28 27 3.9 (2.6-5.3) 26 10.8 (5.2-14.9) 86 72 4.7 (2.6-5.7) 61 12.4 (8.2-17.2)
 Yes 13 11 4.7 (1.9-8.7) 0.681 9 13.7 (3.9-16.7) 0.997 1 1 2.1 (-) 0.281 1 3.0 (-) 0.045
Mucositis
 No 40 37 3.8 (2.6-5.7) 34 11.2 (6.7-14.9) 81 68 4.6 (2.6-5.7) 57 11.8 (8.2-17.2)
 Yes 1 1 15.3 (-) 0.397 1 15.8 (-) 0.762 6 5 4.8 (1.1-nr) 0.439 5 9.8 (2.2-nr) 0.917
PFS, progression-free survival; OS, overall survival; BCLC, Barcelona-Clinic Liver Cancer; MELD, Model For End-Stage Liver Disease
* diastolic pressure >90 mmHg or systolic pressure >140 mmHg recorded 15 days after the start of sorafenib treatment
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P = 0.03, respectively) (Table 5). These data remained 
statistically significant after Bonferroni correction.
eNOS genotypes and clinical outcome in the 
validation cohort
In univariate analysis, we confirmed that all 3 SNPs 
were associated with PFS (Table 3 and Supplementary Figure 
2A-2C). eNOS-786 TT, eNOS VNTR 4bb and eNOS+894 GG 
were significantly associated with a lower median PFS (2.0, 
2.5 and 2.5 months, respectively) than the other genotypes 
(6.9, 6.1 and 6.9 months, respectively) (P < 0.0001, P = 
0.01 and P = 0.001, respectively). We also confirmed that 
patients homozygous for HT1 had a lower median PFS than 
those with other haplotypes (2.0 vs. 6.7 months, P < 0.0001) 
(Table 3 and Figure 1C). These results remained statistically 
significant after Bonferroni correction.
With regard to OS, eNOS-786 TT, eNOS VNTR 
4bb and eNOS+894 GG genotypes were significantly 
associated with a lower median OS (6.4, 10.5 and 7.5 
months, respectively) than the other genotypes (19.5, 19.5 
and 14.1 months, respectively) (P = 0.0001, P = 0.048, 
P = 0.027, respectively) (Table 4 and Supplementary 
Figure 2D–2F). We also found that patients homozygous 
for haplotype HT1 had a lower median OS than those 
with other haplotypes (6.4 vs.18.0 months, respectively, 
P < 0.0001) (Table 4 and Figure 1D). This result remained 
statistically significant after Bonferroni correction.
Following adjustment for clinical covariates (age, 
gender, etiology, BCLC stage, serum α-FP level and 
MELD score), multivariate analysis confirmed the eNOS 
haplotype as the only independent prognostic factor 
predicting PFS (HR 11.17, 95%CI 3.71-33.63, P < 0.0001) 
and OS (HR 7.03, 95%CI 1.86-26.55, P = 0.004). These 
data remained statistically significant after Bonferroni 
correction (Table 5). Furthermore, no significant 
associations were observed between eNOS polymorphisms 
and hypertension, skin toxicity, asthenia, mucositis or 
diarrhea in the validation cohort (data not shown).
eNOS genotypes and objective response rate 
(ORR) in the training and validation cohort
eNOS polymorphisms were also investigated in 
relation to ORR (Supplementary Table 2). In the training 
cohort, patients carrying a TT genotype for eNOS-786 
showed a higher percentage of progression at the first 
CT re-evaluation than those carrying other genotypes 
(76.9% vs. 34.8%, respectively) (P = 0.013). These data 
were confirmed in the validation cohort (55.6% vs. 3.7%, 
respectively) (P < 0.0001).
In the training cohort, patients carrying homozygous 
HT1 showed a higher percentage of progression at the 
first CT re-evaluation than those carrying other haplotypes 
(76.9% vs. 31.8%, respectively) (P = 0.009). These data 
were confirmed in the validation group (57.7% vs. 3.7%, 
Table 3: Univariate analysis of PFS according to eNOS polymorphisms in the training and validation cohorts
Training cohort Validation cohort
No. of 
Patients
No. of 
Events
Median PFS  
(95% CI)
HR  
(95% CI)
P No. of 
Patients
No. of 
Events
Median PFS  
(95% CI)
HR  
(95% CI)
P
Overall 38 3.9 (2.7-5.7) - - 73 4.6 (2.6-5.7) - -
eNOS-786
 TT 15 15 2.6 (1.1-2.8) 4.43 (2.08-9.42) 0.0001 37 35 2.0 (1.6-2.1) 5.81 (3.43-9.82) <0.0001
 CC+TC 26 23 5.8 (3.8-8.7) 1.00 50 38 6.9 (5.6-14.5) 1.00
eNOS VNTR
 4bb 26 25 2.8 (2.3-4.6) 2.08 (1.01-4.29) 0.046 62 52 2.5 (2.1-4.8) 1.97 (1.18-3.31) 0.010
 4ab+4aa 13 11 8.5 (3.8-15.3) 1.00 24 21 6.1 (4.7-23.9) 1.00
eNOS+894
 GG 18 16 2.8 (2.3-3.8) 2.00 (1.00-3.99) 0.049 42 40 2.5 (2.0-3.7) 2.17 (1.35-3.49) 0.001
 GT+TT 23 22 5.5 (3.7-8.5) 1.00 45 33 6.9 (4.8-12.8) 1.00
eNOS Haplotypes * (786/
VNTR)
 HT1/HT1 14 14 2.6 (1.1-2.8) 5.43 (2.46-11.98) <0.0001 35 33 2.0 (1.6-2.1) 5.16 (3.06-8.68) <0.0001
 Other 25 22 5.8 (3.8-8.7) 1.00 51 40 6.7 (5.0-13.8) 1.00
PFS, progression-free survival; OS, overall survival; HR, hazard ratio.
*Haplotypes (HT) 1 shows the allele T at eNOS-786 and allele 4b at eNOS VNTR. “Other” indicates haplotypes other than the one indicated.
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respectively) (P < 0.0001). We also observed that patients 
homozygous for haplotype HT1 in either cohort showed 
a lower percentage of complete and partial response (0% 
and 3.8, respectively) than those carrying other haplotypes 
(18.2% and 18.5%, respectively) at the first CT re-evaluation.
DISCUSSION
Our study of 2 independent cohorts (training and 
validation) revealed that advanced HCC patients homozygous 
for a specific eNOS haplotype showed the worst PFS and 
OS. Few biomarkers predicting drug response are available 
in clinical practice for many cancer types [28, 29] and as 
far as we know this is the first study to demonstrate the role 
of eNOS polymorphisms in relation to clinical outcome in 
advanced HCC patients receiving sorafenib.
We found that patients homozygous for eNOS 
haplotype in most cases showed disease progression at 
the first CT re-evaluation. Moreover, patients with other 
genotypes associated with a better PFS and OS showed 
higher response rates.
Several clinical trials have been performed on the 
combined use of transarterial chemoembolization (TACE) 
and sorafenib [4, 30–34]. However, these studies did not 
succeed in their primary aim because patients were not 
selected on the basis of molecular markers.
The results obtained from our analysis of eNOS 
polymorphisms suggest that they could identify potential 
candidates for treatment with combination therapies 
including TACE-sorafenib and could help to evaluate 
the efficacy of sorafenib in patients without good liver 
function (Child-Pugh B).
In the literature, only a few studies have identified 
possible markers of response to sorafenib in HCC patients. 
Post-hoc analysis of the SHARP study demonstrated 
that low baseline plasma concentrations of VEGF-A 
Figure 1: eNOS haplotypes and clinical outcome in the two independent cohorts. A-C. Progression-free survival (PFS) and 
B-D. overall survival (OS) in relation to eNOS haplotypes (HT) in the training and validation cohorts. Other, haplotypes other than the one 
indicated.
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and angiopoietin-2 were associated with better OS [6, 
35], but this has not been confirmed by other authors. 
Polymorphism analysis seems to have more advantages 
than protein or gene expression analysis. Gene expression 
analysis is performed on biological material collected at 
a specific time in the natural history of the disease. It is 
also subject to the influence of a number of laboratory 
biases. Conversely, polymorphism analysis can be 
performed at any time during the course of the disease, 
is not substantially influenced by laboratory biases 
Table 4: Univariate analysis of OS according to eNOS polymorphisms in the training and validation cohorts
Training cohort Validation cohort
No. of 
Events
Median OS (95% 
CI)
HR (95% CI) P No. of 
Events
Median OS 
(95% CI)
HR (95% CI) P
Overall 35 11.3 (6.7-14.9) - - 62 12.4 (8.2-17.2) - -
eNOS-786
 TT 13 3.9 (2.1-8.7) 1.85 (0.91-3.77) 0.088 29 6.4 (3.7-10.5) 3.41 (1.96-5.95) <0.0001
 CC+TC 22 14.6 (10.4-15.8) 1.00 33 19.5 (12.4-29.0) 1.00
eNOS VNTR
 4bb 22 6.9 (3.2-14.9) 1.21 (0.57-2.59) 0.621 44 10.5 (6.4-14.1) 1.76 (1.00-3.09) 0.048
 4ab+4aa 11 14.6 (10.1-15.8) 1.00 18 19.5 (8.2-31.5) 1.00
eNOS+894
 GG 13 7.5 (3.2-16.7) 1.38 (0.67-2.84) 0.387 35 7.5 (4.9-17.2) 1.79 (1.07-2.99) 0.027
 GT+TT 22 12.8 (6.8-15.6) 1.00 27 14.1 (11.2-27.0) 1.00
eNOS Haplotypes *  
(786/VNTR)
 HT1/HT1 12 3.2 (2.1-6.8) 2.35 (1.12-4.91) 0.024 27 6.4 (3.7-10.5) 3.01 (1.73-5.23) <0.0001
 Other 21 14.6 (10.4-15.8) 1.00 35 18.0 (11.3-28.6) 1.00
PFS, progression-free survival; OS, overall survival; HR, hazard ratio.
*Haplotypes (HT) 1 shows the allele T at eNOS-786 and allele 4b at eNOS VNTR. “Other” indicates haplotypes other than the one indicated.
Table 5: Multivariate analysis in the training and validation cohorts
Training cohort Validation cohort
PFS OS PFS OS
HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
eNOS-786
 CT+CC 1.00 1.00 1.00 1.00
 TT 10.24 (2.88-36.45) 0.0003 4.98 (1.48-16.69) 0.009 5.87 (1.28-26.99) 0.023 0.56 (0.04-8.29) 0.677
eNOS VNTR
 4ab+4aa 1.00 1.00 1.00 1.00
 4bb 0.83 (0.31-2.21) 0.703 0.46 (0.16-1.29) 0.141 3.31 (0.67-16.31) 0.141 7.04 (0.70-70.73) 0.097
eNOS+894
 GT+TT 1.00 1.00 1.00 1.00
 GG 1.16 (0.48-2.79) 0.741 0.59 (0.21-1.64) 0.309 1.48 (0.44-5.04) 0.528 11.95 (1.15-24.12) 0.038
eNOS Haplotypes*
 Other 1.00 1.00 1.00 1.00
 HT1/HT1 9.76 (3.19-29.85) <0.0001 2.64 (1.10-6.34) 0.030 11.17 (3.71-33.63) <0.0001 7.03 (1.86-26.55) 0.004
PFS, progression-free survival; OS, overall survival; HR, hazard ratio.
* HT1 shows the allele T at eNOS-786 and allele 4b at eNOS VNTR. “Other” indicates haplotypes other than the one indicated.
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and is less expensive. In this regard, only one study on 
polymorphisms and response to sorafenib showed that 
VEGF-A and VEGF-C polymorphisms were independent 
factors influencing PFS and OS [36].
Previous studies suggested that DNA variants at the 
eNOS gene can quantitatively control eNOS expression 
[25, 37]. The point variation at nucleotide-786bp has 
been associated with a significant reduction in eNOS gene 
promoter activity, resulting in lower levels of eNOS mRNA, 
eNOS protein and enzyme activity [24, 37]. With regard to 
the variable number tandem repeat, the rare allele 4-repeat 
homozygote shows the highest eNOS mRNA levels, which 
are, however, associated with lower eNOS protein levels 
and enzyme activities [24, 37]. It has also been suggested 
that this polymorphism modulates eNOS expression though 
the formation of small RNAs (sirRNAs). Endothelial cells 
containing 5 repeats show higher quantities of sirRNA and 
lower levels of eNOS mRNA when compared with cells 
containing 4 repeats [38, 39]. In addition, eNOS+894G>T 
variation in exon 7 of the eNOS gene, leading to an amino 
acid change from Glu to Asp (Glu298Asp), is associated 
with reduced eNOS protein levels, enzyme activities 
and basal NO production [40, 41]. Moreover, Wang et al. 
demonstrated that the functional 27-bp repeat at intron 4 
coordinates with the eNOS-786 variant and may directly 
affect transcription efficiency [25].
In our study, TT homozygotes for the eNOS-786 
variant, allele 5-repeat homozygotes for eNOS VNTR and 
GG homozygotes for +894 variant resulted in lower PFS 
and OS. In agreement with previous studies, these kinds of 
variants seem to be associated with higher eNOS protein 
levels and enzyme activities, and consequently with 
increased basal NO production. We therefore hypothesized 
an association between high levels of eNOS protein/
activity and sorafenib resistance.
With regard to toxicity, we found that patients 
with hypertension during sorafenib treatment showed 
better PFS and OS, as previously observed [42, 43]. An 
increased in blood pressure seems to be closely related 
to eNOS. The activation of VEGFR-2 also stimulates 
the production of NO and inhibits endothelin-1 (ET-
1), a potent vasoconstrictor [44, 45]. In patients treated 
with sorafenib, inhibition of VEGFR-2 may reduce NO, 
resulting in vasoconstriction and hypertension.
The main strength of our multicenter study is that the 
analyses were performed on two independent cohorts of 
patients. Moreover, patients in the validation cohort were 
treated by different specialists (oncologist, gastroenterologist 
and hepatologist). The study also has a number of 
limitations, e.g. its retrospective nature (cases were, however, 
consecutively selected, thus reducing potential bias). Thus, 
we were only able to collect data on hypertension for the 
training cohort. In a previous work we found that the early 
onset of hypertension was associated with improved clinical 
outcome in HCC patients treated with sorafenib [46]. Given 
the possible correlation between eNOS polymorphisms and 
hypertension [27], it would have been interesting to evaluate 
this in our validation cohort. As our study was carried out on 
white individuals only, our findings cannot be automatically 
extrapolated to patients of other ethnicities. Another limitation 
of our study is the absence of a control arm not receiving 
sorafenib. Thus, a clear distinction cannot be made between 
the prognostic and predictive role of eNOS polymorphisms 
in relation to survival.
In conclusion, the presence of a specific haplotype of 
eNOS-786 and eNOS VNTR polymorphisms may identify a 
subset of HCC patients who are more resistant to sorafenib. 
These data now require confirmation in a prospective study.
MATERIALS AND METHODS
Patients and treatment
This retrospective multicenter Italian study was 
conducted on a training cohort of 41 HCC patients 
consecutively treated at Istituto Scientifico Romagnolo 
per lo Studio e la Cura dei Tumori from 2012 to 2014. A 
retrospective validation cohort of 87 HCC patients was 
consecutively recruited by four other participating centers 
(Faenza Hospital and the Universities of Ancona, Milan 
and Bari) from 2012 to 2015.
Patients receiving sorafenib with advanced- or 
intermediate-stage HCC (either histologically proven or 
diagnosed according to the AASLD [American Association 
for the Study of Liver Diseases 2005] guidelines) refractory 
or no longer amenable to locoregional therapies, were 
eligible for our analysis. Eligibility criteria were the same 
as those of Llovet’s pivotal study on sorafenib in HCC: [3] 
Eastern Cooperative Oncology Group (ECOG) performance 
status score ≤2 ; Child-Pugh liver function class A; 
adequate hematologic function (platelet count, ≥60×109/L; 
hemoglobin ≥8.5 g/dL; and prothrombin time international 
normalized ratio ≤2.3 or prothrombin time ≤6 seconds above 
control, adequate hepatic function (albumin ≥2.8 g/dL; total 
bilirubin ≤3 mg/dL [51.3 μmol/L]; alanine aminotransferase 
and aspartate aminotransferase ≤5 times the upper limit 
of the normal range); and adequate renal function (serum 
creatinine ≤1.5 times the upper limit of the normal range).
All patients received sorafenib according to the 
standard schedule (400 mg bid continuously), dose 
reductions applied when clinically indicated. Follow-up 
consisted of a CT/MRI scan every 8 weeks or as clinically 
indicated. Tumor response was evaluated by modified 
Response Evaluation Criteria in Solid Tumors (mRECIST) 
[47]. Treatment with sorafenib was continued until disease 
progression, unacceptable toxicity or death.
Hypertension was defined as an increase in 
systolic blood pressure (> 140 mmHg) and/or in 
diastolic blood pressure (> 90 mmHg) after 15 days’ 
treatment with sorafenib. The Model For End-Stage 
Liver Disease (MELD) score cutoff was 10 [48]. The 
study was approved by the Local Ethics Committees of 
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each center and informed consent was obtained from 
each patient for their biological material to be used for 
research purposes.
DNA isolation and genotyping
On the basis of our previous results confirming 
that eNOS polymorphism analysis is feasible regardless 
of the starting material used [49], we performed eNOS 
genotyping using DNA extracted from whole blood or 
formalin-fixed paraffin-embedded (FFPE) HCC tissue. 
For peripheral blood samples collected in EDTA tubes, 
genomic DNA was extracted from 200 μl of whole blood 
by QIAamp DNA Minikit (Qiagen SPA, Milan, Italy) 
in accordance with the manufacturer’s instructions. For 
tissue samples, paraffin wax was removed with xylene 
and samples were washed twice with 100% ethanol. 
DNA was isolated from the deparaffinized tissue using 
the Recover-AllTM Total Nucleic Acid Isolation Kit for 
FFPE Tissues (Applied Biosystems, Foster City, CA) in 
accordance with the manufacturer’s instructions. DNA 
quantity and quality were assessed by Nanodrop 1000 
(Celbio, Milan, Italy).
SNPs in the eNOS gene are well documented 
polymorphisms and were selected after a review of the 
medical literature. eNOS-786 T>C (rs2070744) is located 
in 5′ promoter region, eNOS VNTR 27bp 4a/b in intron 4 
and eNOS+894G>T (rs1799983) in exon 7. eNOS VNTR 
27bp 4a/b in intron 4 has 2 common alleles: “4a” with 4 
repeats and “4b” with 5 repeats.
Genotyping analyses of eNOS-786 and eNOS+894 
were performed by TaqMan technology using SNP 
genotyping assays. Polymerase chain reaction (PCR) 
was performed and genotypes were analyzed on the 
7500 Real-Time PCR System (Applied Biosystems) 
using a 7500 Software version 2.3. PCRs were performed 
starting from 20 ng of genomic DNA. Conversely, 
eNOS VNTR was determined by standard PCR and 
direct sequencing analysis on an ABI 3130 Genetic 
Analyser (Applied Biosystems). PCR conditions and 
primer sequences for eNOS VNTR were reported in our 
previous study [49]. All samples were analyzed at the 
same institution (Biosciences Laboratory, IRST IRCCS, 
Meldola, Italy).
Statistical analysis
Hardy-Weinberg equilibrium, linkage disequilibrium 
and haplotype analyses were performed using the 
Haploview program version 4.2 [50]. This software 
provides Lewontin’s disequilibrium coefficient (D’) as 
the measure of the nonrandom association of alleles at 
different loci. The D’ coefficient is equal to 1 only if 2 
SNPs have not been separated by recombination (or 
recurrent mutation) during the history of the sample 
(complete degree of linkage disequilibrium [LD]).
The primary objective of this study was to evaluate 
the prognostic value of eNOS polymorphisms in relation 
to clinical outcome (PFS and OS) in a cohort of advanced 
HCC patients undergoing sorafenib treatment (training 
cohort). The second objective was to verify whether 
eNOS polymorphisms are related to objective response. 
The prognostic value of eNOS polymorphisms in patients 
with advanced HCC was then confirmed in an independent 
cohort (validation cohort).
PFS was defined as the time from the first 
administration of sorafenib until the first report of 
objective disease progression or death due to any 
cause, whichever occurred first, or until the date of the 
last follow-up. OS was defined as the time from the 
first administration of sorafenib until death due to any 
cause, or until the date of the last follow-up. Event-time 
distributions were estimated using the Kaplan-Meier 
method and survival curves were compared using the 
log-rank test.
Cox proportional hazard ratios were identified 
separately for each polymorphism. The significance 
threshold for an overall type I error rate of 0.05 was 
set at P < 0.0062 based on a conservative Bonferroni 
correction for multiple comparison. We subsequently 
analyzed significant polymorphisms identified in this 
step using Cox regression analysis adjusting for baseline 
covariates (age, gender, etiology, Barcelona-Clinic Liver 
Cancer [BCLC] stage, serum α-FP level and MELD 
score).
The association between polymorphisms and 
objective response (OR, defined as complete/partial 
response vs. stable disease vs. progressive disease) 
was examined using the Chi-Square test with a 
significance level of P = 0.05. All statistical analyses 
were performed using SAS Statistical Software (version 
9.3, SAS Institute Inc., Cary, NC). All P values were 
two-sided.
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